| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Pelitrexo (150 nM; 24 h) significantly suppresses mTORC1 activity in A549 cells by lowering intracellular guanine nucleotide and GTP-bound Rheb protein levels [1]. In NCI-H460 cells, pelitrexo (0-1000 mM; 16 h) dose-dependently and potently suppresses the phosphorylation levels of ribosomal protein S6 (S6RP), S6K1, and Chk1 [1]. In NCI-H460 cells, pelitrexo (100 nM; 48 h) stops the cell cycle in the G1 phase [1].
|
|---|---|
| ln Vivo |
Pelitrexo (10 mg/kg, 20 mg/kg; i.p.; every 4 days for 3 weeks) inhibits the growth of tumors and mTORC1 in mice with xenografts of non-small cell lung cancer (NSCLC) [1]. Pelitrexo (20 mg/kg; i.p.; every 4 days for 3 weeks) suppresses the function of mTORC1 and inhibits purine biosynthesis that is dependent on GARFT [1].
|
| Cell Assay |
Cell cycle analysis[1]
Cell Types: NCI-H460 NSCLC Tested Concentrations: 100 nM Incubation Duration: 4, 8, 24, 48 hrs (hours) Experimental Results: 63% of cells accumulated in the G1 phase of the cell cycle. Cell cycle analysis[1] Cell Types: NCI-H460 NSCLC Tested Concentrations: 0, 10, 30, 100, 300, 1000 nM Incubation Duration: 16 hrs (hours) Experimental Results: Inhibition of p-S6RP, p-S6K1 and p-Chk1 levels. |
| Animal Protocol |
Animal/Disease Models: Mouse non-small cell lung cancer (NSCLC) xenograft model [1]
Doses: 10 mg/kg, 20 mg/kg Route of Administration: intraperitoneal (ip) injection; Group 1 once every 4 days for 3 weeks; Group 2 The results of administration on days 1, 4, and 7 of each group: In group 1, 10 mg/kg and 20 mg/kg inhibited tumor growth by 64% and 69%, respectively. Inhibits mTORC1-dependent phosphorylation of S6K1, S6RP and CAD Group 2 20 mg/kg. |
| References | |
| Additional Infomation |
Pelitrexol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Pelitrexol is a water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation |
| Molecular Formula |
C20H25N5O6S
|
|---|---|
| Molecular Weight |
463.5074
|
| Exact Mass |
463.152
|
| CAS # |
446022-33-9
|
| PubChem CID |
135431074
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.743
|
| LogP |
-0.58
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
859
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N
|
| InChi Key |
QXOPTIPQEVJERB-JQWIXIFHSA-N
|
| InChi Code |
InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
|
| Chemical Name |
(2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~53.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1575 mL | 10.7873 mL | 21.5745 mL | |
| 5 mM | 0.4315 mL | 2.1575 mL | 4.3149 mL | |
| 10 mM | 0.2157 mL | 1.0787 mL | 2.1575 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
